Physician profile
Gary Gerstenblith
NPI 1477591758
$3,346.12
in general payments reported to CMS, 2019-2025
2 companies · $3,346 in 2025
The $3,346 reported for 2025 was more than what 89% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $3,346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,140 · Food and Beverage: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,140.00 |
| Food and Beverage | $206.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,200.32 | 2025 | |
| Merck Sharp & Dohme LLC | $145.80 | 2025 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Gerstenblith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.